Evidence-based Stimulation Trial With Human rFSH in Europe and Rest of World 2

Phase 3CompletedNCT01956123

Ferring Pharmaceuticals513 enrolled

Overview

This trial investigates the immunogenicity of FE 999049 in repeated cycles.

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

TREATMENT

Masking

SINGLE

Enrollment

513

Conditions

Infertility

Interventions

Follitropin Delta (FE 999049)DRUG

Follitropin Alfa (GONAL-F)DRUG

Eligibility

Sex: FEMALEMin age: 18 YearsMax age: 40 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Informed Consent Documents signed prior to screening evaluations related to this protocol * Participation in the pivotal efficacy trial (trial 000004/ESTHER-1) * Anti-FSH antibody results from baseline and at least one post-dosing assessment in the previous cycle(s) available. * Having undergone the oocyte retrieval procedure, or having had cycle cancellation prior to oocyte retrieval due to poor ovarian response or excessive ovarian response, in the previous cycle(s). * Failure to achieve ongoing pregnancy in the previous cycle(s). Exclusion Criteria: * Non-compliance to protocol compliance in the previous cycle(s). * Having undergone any stimulation with gonadotropins since the end-of-trial / end-of-cycle visit in the previous cycle * One or more follicles ≥10 mm observed on the transvaginal ultrasound prior to start of dosing on stimulation day 1 * Severe OHSS in a previous cycle. * Any clinically relevant change to any of the eligibility criteria in the previous cycle(s). * Clinically relevant medical history since the previous cycle which precludes gonadotropin stimulation or is associated with a reduced chance of pregnancy.

Locations (13)

UZ Brussel (there may be other sites in this country)

Brussels, Belgium

Fertilitat and PUC-RS (there may be other sites in this country)

Porto Alegre, Brazil

Outcomes

Primary Outcomes

Proportion (Percentage) of Subjects With Treatment-induced Anti-Follicle-Stimulating Hormone (FSH) Antibodies After up to Two Repeated Controlled Ovarian Stimulation Cycles

The proportion (percentage) of participants with at least one treatment-induced anti-FSH antibody response at any time point is presented. The cumulative incidences in COS cycle 2 and COS cycle 3 divided by participants in COS cycle 2 are presented. Participants with observations in both cycles are only counted once.

Time frame: Stimulation day 1, 7-10 days after last FE 999049 or GONAL-F dose and 21-28 days after last FE 999049 or GONAL-F dose

Secondary Outcomes

Proportion (Percentage) of Subjects With Treatment-induced Anti-FSH Antibodies With Neutralising Capacity After up to Two Repeated Controlled Ovarian Stimulation Cycles

The proportion (percentage) of participants with treatment-induced anti-FSH antibodies with neutralising capacity at any time point is presented. The cumulative incidences in COS cycle 2 and COS cycle 3 divided by participants in COS cycle 2 are presented. Participants with observations in both cycles are only counted once.

Time frame: Stimulation day 1, 7-10 days after last FE 999049 or GONAL-F dose and 21-28 days after last FE 999049 or GONAL-F dose

Proportion (Percentage) of Subjects With Treatment-induced Anti-FSH Antibodies, Overall as Well as With Neutralising Capacity, After One and After Two Repeated Controlled Ovarian Stimulation Cycles

The proportion (percentage) of participants with treatment-induced anti-FSH antibodies, overall as well as with neutralising capacity, after one and after two repeated COS cycles is presented.

Time frame: Stimulation day 1, 7-10 days after last FE 999049 or GONAL-F dose and 21-28 days after last FE 999049 or GONAL-F dose

Proportion (Percentage) of Subjects With Early Ovarian Hyperstimulation Syndrome (OHSS) (Including OHSS of Moderate/Severe Grade) and/or Preventive Interventions for Early OHSS for Each Controlled Ovarian Stimulation Cycle

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.

Pacific Centre for Reproductive Medicine

Burnaby, British Columbia, Canada

Olive Fertility Centre

Vancouver, British Columbia, Canada

Ottawa Fertility Centre

Ottawa, Ontario, Canada

IVF CUBE SE (there may be other sites in this country)

Prague, Czechia

Rigshospitalet Fertilitetsklinikken (there may be other sites in this country)

Copenhagen, Denmark

Department of Endocrine Gynaecology and Reproductive Medicine, Hôpital Jeanne de Flandre (there may be other sites in this country)

Lille, France

Centro Natalità San Raffaele (there may be other sites in this country)

Milan, Italy

The nOvum Clinic (there may be other sites in this country)

Warsaw, Poland

...and 3 more locations

The proportion (percentage) of participants with early OHSS, early OHSS of moderate or severe grade, preventive interventions for early OHSS, early OHSS and/or preventive interventions for early OHSS, and early OHSS of moderate or severe grade and/or preventive interventions for early OHSS are presented.

Time frame: ≤9 days after triggering of final follicular maturation.

Proportion (Percentage) of Subject With Cycle Cancellation Due to Poor Ovarian Response or Excessive Ovarian Response for Each Controlled Ovarian Stimulation Cycle

Proportion (percentage) of participants with cycle cancellation due to poor ovarian response, excessive ovarian response, and triggering with gonadotropin-releasing hormone (GnRH) agonist are presented.

Time frame: End-of-stimulation (up to 20 stimulation days)

Vital Pregnancy Rate for Each Controlled Ovarian Stimulation Cycle

Vital pregnancy was defined as at least one intrauterine gestational sac with fetal heart beat 5-6 weeks after blastocyst transfer.

Time frame: 5-6 weeks after blastocyst transfer

Implantation Rate for Each Controlled Ovarian Stimulation Cycle

Implantation rate was defined as the number of gestational sacs 5-6 weeks after transfer divided by number of blastocysts transferred.

Time frame: 5-6 weeks after blastocyst transfer

Ongoing Pregnancy Rate for Each Controlled Ovarian Stimulation Cycle

Ongoing pregnancy rate was defined as at least one intrauterine viable fetus 10-11 weeks after blastocyst transfer.

Time frame: 10-11 weeks after blastocyst transfer

Ongoing Implantation Rate for Each Controlled Ovarian Stimulation Cycle

Ongoing implantation rate was defined as the number of intrauterine viable fetuses 10-11 weeks after transfer divided by number of blastocysts transferred.

Time frame: 10-11 weeks after blastocyst transfer

Frequency of Injection Site Reactions (Redness, Pain, Itching, Swelling and Bruising) Assessed by the Subject During the Stimulation Period for Each Controlled Ovarian Stimulation Cycle

Participants self-assessed injection site reactions (redness, itching, pain, swelling and bruising) immediately, 30 minutes and 24 hours after each injection. The injection site reactions were assessed as none, mild, moderate and severe. The frequency of injection site reactions (mild, moderate or severe) based on all assessment performed is presented.

Time frame: End-of-stimulation (up to 20 stimulation days)

Proportion (Percentage) of Subjects With Late OHSS (Including OHSS of Moderate/Severe Grade) for Each Controlled Ovarian Stimulation Cycle

Late OHSS was defined as OHSS with onset \>9 days after triggering of final follicular maturation.

Time frame: >9 days after triggering of final follicular maturation

Technical Malfunctions of the Administration Pen for Each Controlled Ovarian Stimulation Cycle

Incidences of confirmed technical malfunction of administration pen are presented.

Time frame: End-of-stimulation (up to 20 stimulation days)